DBV shares are crushed — while ri­val Aim­mune soars — af­ter PhI­II flop for peanut al­ler­gy med

A cou­ple of years ago, Paris-based DBV Tech­nolo­gies $DB­VT set aside $95 mil­lion from an of­fer­ing for its Phase III tri­al of a new ther­a­py for peanut al­ler­gies.

On Fri­day, af­ter the US mar­ket closed, DBV an­nounced that the Phase III flopped, with their treat­ment un­able to mark a sta­tis­ti­cal­ly sig­nif­i­cant sep­a­ra­tion from a place­bo arm as de­fined by the tri­al pro­to­col. But the French biotech adds that they aren’t let­ting a pri­ma­ry end­point fail­ure stop them from fil­ing a new drug ap­pli­ca­tion with the FDA in any case.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN